La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
I-Mab Gestione
Gestione criteri di controllo 1/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Sean Fu
Amministratore delegato
n/a
Compenso totale
Percentuale dello stipendio del CEO | n/a |
Mandato del CEO | less than a year |
Proprietà del CEO | n/a |
Durata media del management | less than a year |
Durata media del Consiglio di amministrazione | 5.1yrs |
Aggiornamenti recenti sulla gestione
Recent updates
I-Mab: Trading Below Net Cash With Multiple Upside Options
Feb 18We're Keeping An Eye On I-Mab's (NASDAQ:IMAB) Cash Burn Rate
Feb 08I-Mab: Another CD47 Inhibitor Biotech With Great Potential
Sep 27I-Mab gets Chinese nod to start phase 3 combo treatment trial for myelodysplastic syndrome
Sep 13I-Mab Biopharma Non-GAAP EPADS of -$1.54, revenue of $7.74M
Aug 30I-Mab and senior executives may buy $40M worth of shares; stock up 10%
Aug 23Newsflash: I-Mab (NASDAQ:IMAB) Analysts Have Been Trimming Their Revenue Forecasts
Aug 20I-Mab doses first patient in phase 1 trial of TJ-CD4B in solid tumors in China
Jul 22I-Mab Valuation Offers A Biotech Investment Opportunity
Jun 23Companies Like I-Mab (NASDAQ:IMAB) Are In A Position To Invest In Growth
May 24I-Mab Shaken By Management Moves, Merger Talk And Delisting Threat
May 06Bearish: Analysts Just Cut Their I-Mab (NASDAQ:IMAB) Revenue and EPS estimates
Apr 01I-Mab Founder Retakes Reins In Latest Shakeup Ahead Of Commercialization Phase
Jan 03I-Mab Gets Boost From Latest Industry Signals On New Cancer Treatment
Oct 14Drug Maker I-Mab Wins Plaudits As Analysts Urge Caution On Soaring Stock
Jul 02AMMINISTRATORE DELEGATO
Sean Fu
less than a year
Mandato
Dr. Xi-Yong Fu, also known as Sean, PhD, MBA, is Director & Interim CEO of I-Mab from July 15, 2024. Along with being Director of I-Mab, Dr. Fu is also an Operating Partner of ABio-X. Before joining ABio-X...
Gruppo dirigente
Nome | Posizione | Mandato | Compensazione | Proprietà |
---|---|---|---|---|
Director & Interim CEO | less than a year | Nessun dato | Nessun dato | |
Chief Financial Officer | less than a year | Nessun dato | Nessun dato | |
Vice President of Investor Relations | no data | Nessun dato | Nessun dato | |
Senior VP and Head of U.S. & EU Business Development | 4.5yrs | Nessun dato | Nessun dato | |
Interim Chief Medical Officer | less than a year | Nessun dato | Nessun dato | |
Chief Medical Officer | less than a year | Nessun dato | Nessun dato | |
Senior Director of Investor Relations | no data | Nessun dato | Nessun dato |
0.4yrs
Durata media
Gestione esperta: Il team dirigenziale di IMAB non è considerato esperto (durata media 0.3 anni), il che suggerisce un nuovo team.
Membri del Consiglio di amministrazione
Nome | Posizione | Mandato | Compensazione | Proprietà |
---|---|---|---|---|
Director & Interim CEO | less than a year | Nessun dato | Nessun dato | |
Member of Scientific Advisory Board | 5.3yrs | Nessun dato | Nessun dato | |
Member of Scientific Advisory Board | 5.2yrs | Nessun dato | Nessun dato | |
Member of Scientific Advisory Board | 5.2yrs | Nessun dato | Nessun dato | |
Independent Director | 4.7yrs | Nessun dato | Nessun dato | |
Independent Director | 4.7yrs | Nessun dato | Nessun dato | |
Chairman | 6.3yrs | Nessun dato | Nessun dato | |
Member of Scientific Advisory Board | 5.1yrs | Nessun dato | Nessun dato | |
Member of Scientific Advisory Board | 5.2yrs | Nessun dato | Nessun dato | |
Member of Scientific Advisory Board | 3.8yrs | Nessun dato | Nessun dato | |
Independent Director | no data | Nessun dato | Nessun dato |
5.1yrs
Durata media
61yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di IMAB sono considerati esperti (durata media dell'incarico 5 anni).